Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 17/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | TGM1 | P22735 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366851 | 1.00 | TRPV1 (0.68) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL1367023 | 1.00 | TRPV1 (0.68) | TRPV1CA12CA1CA2CA9 | |
| SCHEMBL1366858 | 0.90 | TRPV1 (0.69) | TRPV1F13A1TGM2TGM1 | |
| SCHEMBL1369977 | 0.90 | TRPV1 (0.69) | TRPV1F13A1TGM2TGM1 | |
| SCHEMBL1367834 | 0.90 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL1367837 | 0.90 | TRPV1 (0.77) | TRPV1 | |
| SCHEMBL1369050 | 0.88 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL1368684 | 0.88 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL1368707 | 0.88 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL1368356 | 0.83 | TRPV1 (0.71) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
| US-7998982-B2 | Amide derivatives as TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2185538-A2 | TETRAHYDROPYRIDINE CARBOXAMIDE DERIVATIVES AS TRPVL ANTAGONISTS | Abbott Laboratories (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009023539-A2 | TETRAHYDROPYRIDINE CARBOXAMIDE DERIVATIVES AS TRPVL ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885CA12 2921/4885CA1 1146/4885 |
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885CA12 2921/4885CA1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.